Once Sluggish Sleep Apnea Gets Active
This article was originally published in Start Up
Executive Summary
The past year was a busy one in the sleep apnea sector of the respiratory market. All three major segments of the sleep apnea market--sleep testing equipment, continuous positive airway pressure (CPAP) devices, and therapeutic implants--were represented by the year's deals, which include four acquisitions and two venture financings, and we're not even counting the $4.9 billion acquisition of Respironics by Philips, which was announced at the tail end of 2007.
You may also be interested in...
Sleep Apnea Devices: The Changing Of The Guard
The current specialty-dominated care paradigm for sleep apnea can't scale-up to meet the demands of an enormous and serious chronic disease. New companies help move diagnosis and treatment to the physicians that see patients first.
Sleep Apnea Devices: The Changing Of The Guard
The current specialty-dominated care paradigm for sleep apnea can't scale-up to meet the demands of an enormous and serious chronic disease. New companies help move diagnosis and treatment to the physicians that see patients first.
New Avenues in Neuromodulation
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."